Company Search:
Advanced Search
Sponsored Links
Epigenomics AG Company Snapshot
Epigenomics AG operates in the Diagnostic substances sector. In addition to historical fundamental analyses, the complete report available to purchase compares Epigenomics AG with three other pharmaceutical manufacturers in Europe: Biocorp Sa of France (2017 sales of 2.32 million Euro [US$2.62 million] ), Nicox SA of France (2.31 million Euro [US$2.60 million] ), and Biotika a.s. which is based in Slovakia (1.74 million Slovak Koruny [US$1.97 million] of which 1,172% was Substances).

Sales Analysis. Epigenomics AG reported sales of 1.86 million Euro (US$2.10 million) for the year ending December of 2017. This represents a sharp decrease of 55.6% versus 2016, when the company's sales were 4.20 million Euro. Contributing to the drop in overall sales was the 75.2% decline in Products Sales (Own and Third Party), from 2.21 million Euro to 548,000.00 Euro. There were also decreases in sales in Research and Development (down 39.2% to 45,000.00 Euro) . However, these declines were partially offset by the increase in sales of Licenses (up 125.4% to 1.27 million Euro) .
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Epigenomics AG
  Stock Performance Chart for Epigenomics AG
  Stock Data: Recent Stock Performance:
  Current Price (2/15/2019): 1.65
(Figures in Euro)
1 Week -0.1%   13 Weeks -8.9%  
4 Weeks -20.9%   52 Weeks -59.3%  
Epigenomics AG Key Data:
  Ticker: ECX Country: Germany
  Exchanges: FRA Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Diagnostic Substances
  2017 Sales 1,864,000
(Year Ending Jan 2018).
Employees: 46
  Currency: Euro Market Cap: 39,527,637
  Fiscal Yr Ends: December Shares Outstanding: 24,014,360
  Share Type: STAMMAKTIE Closely Held Shares: 8,497,165
Sponsored Links
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.